Xcout Intel
RheumaGen, Inc. competitors & alternatives
The 12 closest competitors and alternatives to RheumaGen, Inc. among cell therapy companies — ranked by similarity to what RheumaGen, Inc. actually does, not by market-cap band.
Subscribe to see RheumaGen, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About RheumaGen, Inc.
RheumaGen, Inc. is a cell and gene therapy company based in Aurora, Colorado, engineering a new class of therapeutics to cure common and major autoimmune diseases such as celiac disease.
RheumaGen, Inc. at a glance
RheumaGen, Inc. is a cell therapy company headquartered in United States. It has raised at least $22.2M across the 5 funding rounds on record, 4 of them with a disclosed amount. Its most recent funding round, Series A, closed in December 2025. Xcout tracks 11 named people at RheumaGen, Inc., including B Robert Mozayeni (Chief Medical Officer).
RheumaGen, Inc. leadership
- B Robert MozayeniChief Medical Officer
- Ryan HartChief Business and Legal Officer
- Richard FreedCEO and Co-Founder
- Brian HartCOO & Co-Founder
- BRIAN FREEDChief Science Officer & Co-Founder
- Dr. Brian FreedChief Science Officer and Co-Founder
5 more named people on record for RheumaGen, Inc., with roles, board committees and tenure — see the full roster →
RheumaGen, Inc. funding rounds
At least $22.2M raised across the 5 rounds on record (4 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | 3 named | |
| Series A | $15M | 2 named | |
| SEC Form D filing | $4.9M | — | |
| SEC Form D filing | $300,000 | — | |
| SEC Form D filing | $2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 RheumaGen, Inc. competitors
Ranked by semantic similarity — how close each company is to RheumaGen, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Nonprofit Organization
Beyond Celiac Investments is an dedicated investment program created by the national organization Beyond Celiac. The initiative is designed to accelerate the development of pharmaceutical treatments and a definitive cure for celiac disease. It bridges patient advocacy with biotech venture funding to fast-track medical research.
Biopharmaceuticals
Alba Therapeutics Corp. was a U.S. biopharmaceutical company focused on therapies for gastrointestinal and autoimmune disorders. Its lead program was larazotide acetate, an investigational zonulin antagonist intended to help patients with celiac disease by reducing intestinal permeability.
Drug Discovery
COUR Pharmaceuticals is a clinical-stage biotechnology company headquartered in Evanston, Illinois, founded in 2015. The firm focuses on reprogramming the immune system to develop novel treatments for autoimmune diseases.
Regenerative Medicine
GenesisTissue Inc. is a 3D bioprinting tissue company based at the CSU Spur campus in Denver, Colorado. The biotech startup designs and manufactures personalized regenerative tissue implants for humans.
Non-profit Organization
The Celiac Disease Foundation is a non-profit organization dedicated to driving research, education, and advocacy for celiac disease.
Biotherapeutics
Headquartered in South San Francisco, California, Chimera Bioengineering is a privately held biotechnology company focused on developing advanced cellular engineering technologies for cancer therapies.
Regenerative Medicine
CCRM Enterprises Holdings Ltd. acts as a catalyst for commercializing regenerative medicines and cell and gene therapies. The organization bridges academia and industry by providing stakeholders, expertise, specialized infrastructure, and funding to accelerate product development and launch companies.
Drug Discovery
Coultreon Biopharma is a clinical-stage biotechnology company headquartered in Leuven, Belgium, focused on developing next-generation precision medicines for immunology and autoimmune diseases. Backed by substantial venture funding, the company advances innovative therapies.
Drug Discovery
iRegene Therapeutics is a biotechnology company headquartered in Wuhan, China, with additional facilities in Suzhou. The firm specializes in regenerative medicine and advanced cell therapies designed to redefine modern medicine.
Gene Therapy
Mirugen Pty Ltd is a preclinical biotechnology company founded in 2022 and headquartered in Melbourne, Australia, dedicated to reprogramming cells to unlock innate cellular functions.
Drug Discovery
Salvina Therapeutics AG is a Swiss biotechnology research company that develops novel antibodies targeting TNF and TNF superfamily members to address inflammatory and autoimmune diseases. The privately held firm focuses on drug development approaches designed to improve safety and overcome efficacy barriers in these therapeutic areas.
Regenerative Medicine
RegenMed, Inc. operates as a National Science Foundation-funded innovation ecosystem that helps regenerative medicine companies develop, grow, and scale their technologies. The organization provides resources, expertise, and collaboration opportunities to bridge industry, workforce development, and science in order to accelerate commercial applications.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of RheumaGen, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for RheumaGen, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →